# Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

> **NCT00982436** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Vermont** · enrollment: 37 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Docetaxel/cisplatin
- **RADIATION:** Radiotherapy
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00982436
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2012-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982436, "Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00982436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*